Keywords: آگونیست β-طولانی مدت; Asthma; Allergic asthma; Elderly; Aeroallergens; Atopy; IgE; Asthma-COPD overlap syndrome (ACOS); Age of asthma onset; ACOS; Asthma-COPD overlap syndrome; AERD; Aspirin-exacerbated respiratory disease; BMI; Body mass index; COPD; Chronic obstructive pulmo
مقالات ISI آگونیست β-طولانی مدت (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: آگونیست β-طولانی مدت; Asthma control; Conventional ICS; Extrafine beclometasone dipropionate; Extrafine ciclesonide; Extrafine-particle ICS; Fine-particle ICS; Inhaled corticosteroids; Observational studies; Real-life; BDP; Beclometasone dipropionate; CFC; Chlorofluorocarbon;
Keywords: آگونیست β-طولانی مدت; Asthma; obesity; inhaled corticosteroid monotherapy; inhaled corticosteroid combination therapy; marginal structural Cox model; BMI; Body mass index; HFA-BDPeq; Hydrofluroalkane-propelled beclomethasone dipropionate or equivalent; HR; Hazard ratio; ICD-9/
Keywords: آگونیست β-طولانی مدت; Pediatric; Summer camp; Allergy; Anaphylaxis; Asthma; Epinephrine autoinjector; Urgent care; Emergency care; EHR; Electronic health record; ICS; Inhaled corticosteroid; LABA; Long-acting β-agonist; NHANES; National Health and Nutrition Examination Survey
Keywords: آگونیست β-طولانی مدت; Asthma; Asthma exacerbation; Viral infection; Allergy; Prevention; Treatment; Inhaled corticosteroids; Long-acting β2-agonists; Leukotriene antagonist; Anticholinergics; Anti-IgE; Anti-IL5; Systemic corticosteroids; ED; Emergency department; FEV1; Forced
Keywords: آگونیست β-طولانی مدت; Asthma; small airways; spirometry; impulse oscillometry; long-acting β-agonist; formoterol; salmeterol; ACQ; Asthma Control Questionnaire; AX; Reactance area under the curve; FEF25-75; Forced midexpiratory flow between 25% and 75% of forced vital capacit
Keywords: آگونیست β-طولانی مدت; asthma; eosinophil; phase 3; reslizumab; ACQ; Asthma Control Questionnaire; ADA; anti-drug antibody; AE; adverse event; FAS; full analysis set; ICS; inhaled corticosteroid; LABA; long-acting β-agonist; LS; least squares; SABA; short-acting β-agonist;
Keywords: آگونیست β-طولانی مدت; DPI; dry powder inhaler; eNPV; expected net present value; LAMA; long-acting muscarinic antagonist; LABA; long-acting β-agonist; NPV; net present value; pMDI; pressurized metered-dose inhaler; COPD; chronic obstructive pulmonary disease; Estimated net pr
Keywords: آگونیست β-طولانی مدت; Asthma; adults; inhaled corticosteroids; asthma management; AERD; Aspirin-exacerbated respiratory disease; CLCA1; Calcium-activated chloride channel regulator 1; COPD; Chronic obstructive pulmonary disease; Feno; Fraction of exhaled nitric oxide; GP; Gene
Keywords: آگونیست β-طولانی مدت; Asthma; asthma control; quality of life; network meta-analysis; questionnaire; ACQ; Asthma Control Questionnaire; AQLQ; Asthma Quality of Life Questionnaire; ICS; Inhaled corticosteroid; LABA; Long-acting β-agonist; LTRA; Leukotriene receptor antagonist;
Keywords: آگونیست β-طولانی مدت; 6MWT; 6-min walk test; GOLD; Global Initiative for Chronic Obstructive Lung Disease; IC; inspiratory capacity; IPF; idiopathic pulmonary fibrosis; LABA; long-acting β-agonist; LAMA; long-acting muscarinic antagonist; mMRC; modified Medical Research Counc
Keywords: آگونیست β-طولانی مدت; aOR; adjusted OR; ICS; inhaled corticosteroid; LABA; long-acting β-agonist; OCS; oral corticosteroid; PEF; peak expiratory flow;
Keywords: آگونیست β-طولانی مدت; Asthma; asthma control; asthma exacerbations; dupilumab; biomarkers; inhaled corticosteroids; lebrikizumab; long-acting Ã-adrenergic agonists; mepolizumab; omalizumab; reslizumab; severe asthma; therapeutics; ACQ; Asthma control questionnaire; BADGER; Be
Keywords: آگونیست β-طولانی مدت; Asthma phenotypes; biologic therapies; eosinophils; IgE; IL-4; IL-5; IL-13; TH2/type 2 inflammation; ACQ; Asthma Control Questionnaire; DBPC; Double-blind, placebo-controlled; FDA; US Food and Drug Administration; Feno; Fraction of exhaled nitric oxide; I
Keywords: آگونیست β-طولانی مدت; Asthma; Exacerbations; Natural history; Inhaled corticosteroids; Long-acting β-agonists; COPD; Chronic obstructive pulmonary disease; ED; Emergency department; HI; High-intensity asthma treatment; CD-9; International Classification of Diseases, Ninth Rev
Keywords: آگونیست β-طولانی مدت; Asthma; Anti-asthmatic agents; Step down; Withdraw; Discontinue; Decrease; Wean; Cessation; ICS; Inhaled corticosteroid; LABA; Long-acting β-agonist; LTRA; Leukotriene receptor antagonist; RCT; Randomized controlled trial;
Keywords: آگونیست β-طولانی مدت; Asthma; Controller medications; Effectiveness; Inhaled corticosteroids; Leukotriene antagonist; Long-acting β-agonist; ED; Emergency department; hdPS; High-dimensional propensity score; HPHC; Harvard Pilgrim Health Care; HR; Hazard ratio; ICS; Inhaled co
Keywords: آگونیست β-طولانی مدت; Lung sound analysis; Airway inflammation; Bronchial asthma; Ach; Acetylcholine; E-I LF; Expiratory-inspiratory ratio of sound power in the low-frequency range; Exp LF; Sound power during expiration; FeNO; Exhaled nitric oxide; FVC; Forced vital capacity;
Keywords: آگونیست β-طولانی مدت; Asthma; adults; inhaled corticosteroids; asthma management; ACQ; Asthma Control Questionnaire; CalvNO; Alveolar fraction of exhaled nitric oxide; COPD; Chronic obstructive pulmonary disease; CRTH2; Chemoattractant receptor homologous molecule expressed on
Keywords: آگونیست β-طولانی مدت; Childhood severe asthma; Childhood difficult-to-treat asthma; Severe asthma phenotypes; Childhood severe asthma treatment; Review; ACQ; Asthma Control Questionnaire; ACT; Asthma Control Test; ATS; American Thoracic Society; BMI; Body mass index; CT; Compu
Keywords: آگونیست β-طولانی مدت; Pediatrics; Asthma; Physician training; Inhaled corticosteroids; Spirometry; %FEV1; Percentage predicted FEV1; BMI; Body mass index; CT; Computed tomography; CXR; Chest radiography; ED; Emergency department; FVC; Forced vital capacity; GERD; Gastroesophag
Keywords: آگونیست β-طولانی مدت; Asthma; tiotropium; salmeterol; responder analysis; predictor of response; ACD; Asthma control day; ACRN; Asthma Clinical Research Network; FVC; Forced vital capacity; HFA; Hydrofluoroalkane; ICS; Inhaled corticosteroid; LABA; Long-acting β-agonist; LAMA
Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease
Keywords: آگونیست β-طولانی مدت; COPD; Long-acting muscarinic antagonist; Long-acting β-agonist; Safety; Maintenance bronchodilator; AE; adverse event; COPD; chronic obstructive pulmonary disease; GOLD; Global initiative for chronic Obstructive Lung Disease; LABA; long-acting β2-agonis
Long-Acting β-Agonist in Combination or Separate Inhaler as Step-Up Therapy for Children with Uncontrolled Asthma Receiving Inhaled Corticosteroids
Keywords: آگونیست β-طولانی مدت; Asthma; Child; Inhaled corticosteroid; Long-acting β-agonist; Step-up therapy; aOR; Adjusted odds ratio; aRR; Adjusted rate ratio; BDP; Beclomethasone dipropionate; BTS/SIGN; The British Thoracic Society and Scottish Intercollegiate Guidelines Network; C
Childhood asthma exacerbations and the Arg16 β2-receptor polymorphism: A meta-analysis stratified by treatment
Keywords: آگونیست β-طولانی مدت; Adrenergic receptors; asthma; child; disease exacerbation; therapeutics; ADRB2; β2-Adrenoceptor gene; GALA II; Genes-Environments and Admixture in Latino Americans; HWE; Hardy-Weinberg equilibrium; ICS; Inhaled corticosteroid; LABA; Long-acting β-agonis
Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma
Keywords: آگونیست β-طولانی مدت; Asthma; roflumilast; montelukast; phosphodiesterase 4 inhibitors; ACQ; Asthma Control Questionnaire; AE; Adverse event; ANCOVA; Analysis of covariance; ATS; American Thoracic Society; BMI; Body mass index; COPD; Chronic obstructive pulmonary disease; C-SS
Roflumilast added to triple therapy in patients with severe COPD: AÂ real life study
Keywords: آگونیست β-طولانی مدت; COPD exacerbations; Phosphodiesterase-4 inhibitors; Combination therapy; Side effects; AECOPD; acute exacerbation of COPD; ICS; inhaled corticosteroids; LABA; long-acting β-agonist; LAMA; long-acting muscarinic antagonist; PDE-4; phosphodiesterase-4;
Factors Predictive of Airflow Obstruction Among Veterans with Presumed Empirical Diagnosis and Treatment of COPD
Keywords: آگونیست β-طولانی مدت; AFO; airflow obstruction; CHF; congestive heart failure; HTN; hypertension; ICD-9; International Classification of Diseases, Ninth Revision; ICS; inhaled corticosteroid; LABA; long-acting β-agonist; RR; relative risk; VA; US Department of Veterans Affair
Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: AÂ cluster-randomized trial in primary care
Keywords: آگونیست β-طولانی مدت; Quality of life; fraction of exhaled nitric oxide; asthma exacerbations; asthma control; cost-effectiveness; online decision support; ACQ; Asthma Control Questionnaire; Ca; Controlled asthma; EQ-5D; EuroQol classification system; FCa; Feno-driven controll
Predictors of Severe Exacerbations, Poor Asthma Control, and β-Agonist Overuse for Patients with Asthma
Keywords: آگونیست β-طولانی مدت; Asthma; β-agonist; Electronic monitoring; Predictors; Risk; ACQ; Asthma Control Questionnaire; ICS; Inhaled corticosteroid; IQR; Interquartile range; LABA; Long-acting β-agonist; MDI; Metered-dose inhaler; RR; Rate ratio; SMART; Single budesonide-formot
Long-Acting Bronchodilators and Arterial Stiffness in Patients With COPD
Keywords: آگونیست β-طولانی مدت; AE; adverse event; AIx; augmentation index; aPWV; aortic pulse wave velocity; CVD; cardiovascular disease; FF/VI; fluticasone furoate/vilanterol; ICS; inhaled corticosteroid; ITT; intent-to-treat; LABA; long-acting β-agonist; LOCF; last observation carri
Pharmacogenetics: Implications of race and ethnicity on defining genetic profiles for personalized medicine
Keywords: آگونیست β-طولانی مدت; Asthma; genes; pharmacogenetics; response heterogeneity; single nucleotide polymorphism; admixture mapping; ethnic group; ADRB1; β1-Adrenergic receptor; ADRB2; β2-Adrenergic receptor; BADGER; Best Add-on Therapy Giving Effective Response Trial; BARGE; B
One-Year Safety and Efficacy Study of Arformoterol Tartrate in Patients With Moderate to Severe COPD
Keywords: آگونیست β-طولانی مدت; AE; adverse event; HR; hazard ratio; IC; inspiratory capacity; LABA; long-acting β-agonist; LSM; least-squares mean; MMRC; Modified Medical Research Council; QoL; quality of life; RCI; repeated CI; SAE; serious adverse event; TORCH; Towards a Revolution
Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma
Keywords: آگونیست β-طولانی مدت; Asthma; phenotypes; TH2 cell; mast cells; eotaxin; inflammation; sputum; cytokines; eosinophils; IL-4; IL-5; IL-13; IL-17; BME; β-Mercaptoethanol; CLCA1; Chloride channel accessory 1; CPA3; Carboxypeptidase A3; Feno; Fraction of exhaled nitric oxide; LAB
Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: AÂ randomized trial
Keywords: آگونیست β-طولانی مدت; IL-13; IL13Rα1; IL13Rα2; efficacy; safety; pharmacokinetics; pharmacodynamics; ACQ; Asthma Control Questionnaire; ADA; Anti-drug antibody; AE; Adverse event; ECLIA; Electrochemiluminescence immunoassay; Feno; Fraction of exhaled nitric oxide; FPE; Fluti
Arterial Stiffness in COPD
Keywords: آگونیست β-طولانی مدت; AGE; advanced glycation end product; AIx; augmentation index; CRP; C-reactive protein; FMD; flow-mediated vasodilatation; FSC; fluticasone propionate/salmeterol combination; ICS; inhaled corticosteroid; LABA; long-acting β-agonist; MMP-9; matrix metallop
Asthma and lower airway diseaseThe risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: AÂ systematic review and meta-analysis of randomized controlled trials
Keywords: آگونیست β-طولانی مدت; Asthma; antiasthma agents; glucocorticoids; clinical trial; step down; withdraw; discontinue; decrease; wean; cessation; ICS; Inhaled corticosteroid; LABA; Long-acting β-agonist; NAEPP; National Asthma Education and Prevention Program; PEF; Peak expirato
The relationship between combination inhaled corticosteroid and long-acting β-agonist use and severe asthma exacerbations in a diverse population
Keywords: آگونیست β-طولانی مدت; Long-acting β-agonist; inhaled corticosteroid; severe asthma exacerbation; safety; racially and ethnically diverse population; observational study; FDA; US Food and Drug Administration; HR; Hazard ratio; ICS; Inhaled corticosteroid; LABA; Long-acting β-
IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist
Keywords: آگونیست β-طولانی مدت; Pharmacogenetics; pitrakinra; IL-4 receptor; asthma therapy; IL-4 receptor antagonist; Feno; Fraction of exhaled nitric oxide; IL4RA; IL-4 receptor α gene; LABA; Long-acting β-agonist; MAF; Minor allele frequency; SNP; Single nucleotide polymorphism;
Reviews and feature articleAdvances in environmental and occupational respiratory disease in 2010
Keywords: آگونیست β-طولانی مدت; Immunotherapy; allergic disease; occupational respiratory disease; hypoallergens; immunotherapy; AGE; Advanced glycation end product; COPD; Chronic obstructive pulmonary disease; CRS; Chronic rhinosinusitis; LABA; Long-acting β-agonist; mDC; Myeloid dend
Phenotypic Expressions of Childhood Wheezing and Asthma: Implications for Therapy
Keywords: آگونیست β-طولانی مدت; CAMP; Childhood Asthma Management Program; EPR-3; Expert Panel Report 3; FEV1; Forced expiratory volume in 1 second; ICS; Inhaled corticosteroid; LABA; Long-acting β-agonist; LTRA; Leukotriene receptor antagonist; mAPI; Modified Asthma Predictive Index;
Reviews and feature articleAsthma exacerbations: Origin, effect, and prevention
Keywords: آگونیست β-طولانی مدت; Asthma; asthma exacerbations; viral infection; virus; allergy; allergen; pollutant; bacteria; ACQ; Asthma Control Questionnaire; BEC; Bronchial epithelial cell; ICS; Inhaled corticosteroid; LABA; Long-acting β-agonist; NO2; Nitrogen dioxide; PEF; Peak ex
Heterogeneity of severe asthma in childhood: Confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program
Keywords: آگونیست β-طولانی مدت; Allergic sensitization; asthma; severe asthma; asthma guidelines; children; cluster analysis; lung function; phenotype; ATS; American Thoracic Society; GINA; Global Initiative for Asthma; ICS; Inhaled corticosteroid; LABA; Long-acting β-agonist; NAEPP; N
Randomized controlled trial of adherence with single or combination inhaled corticosteroid/long-acting β-agonist inhaler therapy in asthma
Keywords: آگونیست β-طولانی مدت; Asthma; adherence; compliance; inhaled corticosteroids; long-acting β-agonists; ACQ; Asthma Control Questionnaire; FP; Fluticasone propionate; ICS; Inhaled corticosteroid; LABA; Long-acting β-agonist; MDI; Metered-dose inhaler;
Body mass index and phenotype in subjects with mild-to-moderate persistent asthma
Keywords: آگونیست β-طولانی مدت; Asthma; obesity; treatment; severity; ACRN; Asthma Clinical Research Network; BAGS; The Addition of Regular-use to Intermittent Rescue β-Agonist for Patients with Mild Asthma; BARGE; β-Agonist Response by Genotype; BMI; Body mass index; DICE; Dose of In
Impact of Asthma Controller Medications on Clinical, Economic, and Patient-Reported Outcomes
Keywords: آگونیست β-طولانی مدت; ATAQ; Asthma Therapy Assessment Questionnaire; BMI; body mass index; COPD; chronic obstructive pulmonary disease; ED; emergency department; HIPAA; Health Insurance Portability and Accountability Act; ICD-9-CM; International Classification of Diseases, Nin
Managing Asthma in Primary Care: Putting New Guideline Recommendations Into Context
Keywords: آگونیست β-طولانی مدت; ACT; Asthma Control Test; EPR3; Expert Panel Report 3; FeNO; fractionated exhaled nitric oxide; ICS; inhaled corticosteroid; LABA; long-acting β-agonist; NAEPP; National Asthma Education and Prevention Program; RAST; radioallergosorbent test;
Geographic Variation of Spirometry Use in Newly Diagnosed COPD*
Keywords: آگونیست β-طولانی مدت; COPD; diagnosis; health-care delivery; health services research; process assessment (health care); quality of health care; spirometry; AOR; adjusted odds ratio; CI; confidence interval; CPT; current procedural terminology; HEDIS; Healthcare Effectiveness
Formulating an Effective and Efficient Written Asthma Action Plan
Keywords: آگونیست β-طولانی مدت; ACT; Asthma Control Test; ED; emergency department; FACET; Formoterol and Corticosteroids Establishing Therapy; ICS; inhaled corticosteroid; LABA; long-acting β-agonist; NAEPP; National Asthma Education and Prevention Program; PEF; peak expiratory flow;
Interactive effects of steroids and β-agonists on accumulation of type 2 T cells
Keywords: آگونیست β-طولانی مدت; Human; T cells; β-adrenergic receptor; β-agonist; asthma; IL-13; glucocorticosteroid; steroid; IL-2; β2AR; β2-Adrenergic receptor; GM; Geometric mean; Kd; Dissociation constant; LABA; Long-acting β-agonist; PBL; Peripheral blood lymphocyte; SABA; Sho